Members are invited to join us at the following events.
Thursday, January 10 - 08:30 AMView Event Info
Wednesday, January 23 - 04:30 PMView Event Info
Thursday, February 07 - 08:30 AMView Event Info
Wednesday, March 06 - 04:30 PMView Event Info
Thursday, March 07 - 08:30 AMView Event Info
Thursday, April 04 - 08:30 AMView Event Info
Wednesday, April 17 - 04:30 PMView Event Info
Thursday, May 02 - 08:30 AMView Event Info
Wednesday, May 22 - 04:30 PMView Event Info
Thursday, June 06 - 08:30 AMView Event Info
Wednesday, July 10 - 07:30 PMView Event Info
Thursday, July 18 - 08:30 AMView Event Info
Thursday, August 22 - 08:30 AMView Event Info
Wednesday, September 11 - 03:30 PMView Event Info
Thursday, October 03 - 08:30 AMView Event Info
Wednesday, October 23 - 04:30 PMView Event Info
Thursday, November 07 - 08:30 PMView Event Info
Wednesday, November 20 - 04:30 PMView Event Info
VICTOR, N.Y., Dec. 6, 2018 -- Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today that Constellation Brands Ventures (CBV), the company’s corporate venture capital group, intends to invest $100 million in female-founded or female-led businesses in the beverage alcohol space and adjacent categories by 2028 through a new program, Focus on Female Founders. The company has completed its first investments in two specialty beverage companies: Austin Cocktails and Vivify Beverages.
Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative disorders, today announced the addition of three renowned leaders in imaging and molecular biomarkers to the company’s Medical Advisory Board.
DALLAS — Pickup, an Uber-like last-mile delivery service for furniture and other large items, has completed a $5 million round of venture capital funding that will speed up expansion of its operations including entry into new markets.
Expedia Group’s $21.5 million acquisition of Chicago-based ApartmentJet Inc. translates into a windfall for angel investors in Pittsburgh.
BlueTree Venture Fund and BlueTree Allied Angels will realize a 4.3 times return on its combined $450,000 investment in less than a year, said Catherine Mott, founder, CEO and managing partner of 15-year-old Wexford-based BlueTree Capital Group LLC.
BELLEVUE, Wash., Oct. 25, 2018 /PRNewswire/ -- Expedia Group, Inc. (NASDAQ: EXPE) announced today the acquisitions of Pillow, a software solution that helps building owners and managers empower their long-term residents to rent their residences, and ApartmentJet, a software solution enabling the rental of guest suites in multifamily communities. Acquiring Pillow and ApartmentJet will help unlock urban growth opportunities that, over time, will contribute to HomeAway's ability to add an even broader selection of accommodations to its marketplace and marketplaces across Expedia Group brands, ensuring travelers always find the perfect place to stay.
Pittsburgh, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic protection and restoration in Alzheimer’s disease and other neurodegenerative disorders, today announced its sponsorship of the Third International Symposium on Sigma-2 Receptors: Role in Health and Disease.
Just a few weeks ago, an infant boy’s life was saved by a surgeon using the PECA Labs exGraft. Between the mundanity of regulatory compliance and supply-chain management, it could be easy to lose sight of the ultimate impact of our work.
Pittsburgh, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in Alzheimer’s disease and other neurodegenerative disorders, today announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded the Company a multiyear grant expected to total $16.6 million to support the Phase 2 SHINE study of Elayta™ (CT1812).
Pittsburgh, July 23, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in neurodegenerative disorders, today announced that co-founder and Chief Science Officer Susan Catalano, Ph.D. presented additional findings supporting the unique synaptorestorative mechanism of action of Elayta™ (CT1812), Cognition’s lead candidate for the treatment of mild-to-moderate Alzheimer’s disease, at the Alzheimer's Association International Conference (AAIC) in Chicago. Dr. Catalano was invited by the Association to present these results as part of the July 23rd Symposium Session: Translational Research In Reality - What Are The Criteria From Concept To Clinic?
Anglr, a North Side-based startup that provides fishing intelligence through a free app and Bluetooth-connected accessories, has reeled in $3.3 million in Series A funding.